Alto Neuroscience, Inc. (ANRO) announced disappointing results from its Phase 2b trial of ALTO-100 for major depressive disorder (MDD), leading to a significant drop in the company’s stock price. Despite the setback, Alto remains optimistic about its biomarker-driven approach and its other ongoing clinical trials.